Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital | Incyclix Bio
Summary
Incyclix Bio closed a $30 million Series B round led by Boxer Capital, with participation from RA Capital Management and Eshelman Ventures. The company plans to use the funds to advance the clinical development of INX-315, its lead CDK2 inhibitor. Incyclix Bio expects to start a Phase 1/2 proof-of-concept study in cancers such as breast and ovarian cancer. The financing also brings board changes, including a new Boxer Capital representative joining the board and an RA Capital observer role.
Funding
Amount
$30.0M
Total raised
Date
March 31, 2022
Announcement date
Investors
Eshelman Ventures, RA Capital Management
Lead investors
Company
https://incyclixbio.com/
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected